Bibliographic information
Recommendation
Antiviral prophylaxis among pregnant women and adolescent girls. In settings where HBV DNA or HBeAg testing is available, prophylaxis with tenofovir disoproxil fumarate (TDF) is recommended for all HBV-positive (HBsAg-positive) pregnant women with HBV DNA ≥200 000 IU/mL or positive HBeAg (preferably from the second trimester of pregnancy until at least delivery or completion of the infant HBV vaccination series), to prevent the mother-to-child transmission (MTCT) of HBV.
Recommended in favor
Strong
Certainty of evidence
Moderate
Notes and Remarks
The use of the HBeAg recommendation represents an additional option for determining eligibility, but HBeAg RDTs have poor diagnostic performance, which limits their routine use in low- and middle-income countries. TAF may be considered for people (including pregnant women) with impaired kidney function and/or osteoporosis but is not yet approved for hepatitis B treatment in pregnancy (see Chapter 6). TAF is not recommended if eGFR is <15 ml/min.